comparemela.com

Latest Breaking News On - Padmini srikantiah - Page 1 : comparemela.com

Pfizer s pledge for more equal access to RSV shot faces hurdles

Pfizer Inc has pledged to deliver critical new medicines more quickly in low-income nations, but its first such vaccine effort faces hurdles likely to delay distribution in poorer countries by several years, global health officials told Reuters.

Pfizer pledge for more equal access to RSV shot faces hurdles - Stock market news

LONDON (Reuters) - Pfizer Inc has pledged to deliver critical new medicines more quickly in low-income nations, but its first such vaccine effort faces hurdles likely to delay distribution in poorer countries by several years, global health officials told Reuters. Pfizer made a commitment on more equitable access last year, following criticism that it prioritized wealthy nations for doses of its COVID-19 shot early in the pandemic. The company says it wants to shorten a timeline in which poorer countries often get vaccines many years after they are available elsewhere. The drugmaker received a $28 million grant from the Bill and Melinda Gates Foundation in September to support the launch of the respiratory syncytial virus vaccine in poorer countries, where RSV - a common cold-like virus - is much more likely to be lethal for very young children. | 06:17am

Pfizer pledge for more equal access to RSV shot faces hurdles

Maternal Immunization: A Key to Maternal and Infant Health | Bill & Melinda Gates Foundation

Gates Foundation Grants Support Faculty-Led Initiative to Encourage Masking and COVID-19 Vaccines in the Developing World

By Karen Guzman New grants from the Bill & Melinda Gates Foundation (BMGF) are fueling the expansion of a Yale School of Management faculty-led initiative to promote mask-wearing and rural vaccine delivery in the developing world. The BMGF has donated $3 million to the NORM project, which last year established a successful formula for mask-wearing implementation in Bangladesh,

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.